Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: LISATA THERAPEUTICS is not mentioned in the provided information; however, Parse Biosciences has enhanced its Evercode™ WT Mega Kit to analyze up to 384 samples and 1 million cells in a single run, advancing high-throughput research capabilities. Additionally, Neurocrine Biosciences will present at the J.P. Morgan Healthcare Conference on January 13, 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
